Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros










Intervalo de año de publicación
1.
Rev Neurol ; 75(s05): S1-S89, 2022 11 30.
Artículo en Inglés, Español | MEDLINE | ID: mdl-36544369

RESUMEN

This review is based on the previous one published in 2016 (Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol 2016; 63 (Supl 3): S1-S73), incorporating 176 new references, having all the information available in the same document to facilitate the access to the information in one document. This review is focused on the main indications of the drug, as acute stroke and its sequelae, including the cognitive impairment, and traumatic brain injury and its sequelae. There are retrieved the most important experimental and clinical data in both indications.


TITLE: Citicolina: revisión farmacológica y clínica, actualización 2022.Esta revisión se basa en la publicada en 2016 ­Secades JJ. Citicolina: revisión farmacológica y clínica, actualización 2016. Rev Neurol 2016; 63 (Supl 3): S1-S73­, e incorpora 176 nuevas referencias aparecidas desde entonces, con toda la información disponible para facilitar el acceso a toda la información en un único documento. La revisión se centra en las principales indicaciones del fármaco, como los accidentes cerebrovasculares agudos y sus secuelas, incluyendo el deterioro cognitivo, y los traumatismos craneoencefálicos y sus secuelas. Se recogen los principales aspectos experimentales y clínicos en estas indicaciones.


Asunto(s)
Lesiones Traumáticas del Encéfalo , Disfunción Cognitiva , Nootrópicos , Accidente Cerebrovascular , Humanos , Citidina Difosfato Colina/farmacología , Citidina Difosfato Colina/uso terapéutico , Nootrópicos/farmacología , Nootrópicos/uso terapéutico , Accidente Cerebrovascular/tratamiento farmacológico , Disfunción Cognitiva/tratamiento farmacológico , Lesiones Traumáticas del Encéfalo/tratamiento farmacológico
2.
Rev. neurol. (Ed. impr.) ; 75(supl.5): S0-S89, Jul-Dic. 2022. ilus, tab, graf
Artículo en Español | IBECS | ID: ibc-219314

RESUMEN

Esta revisión se basa en la publicada en 2016 –Secades JJ. Citicolina: revisión farmacológica y clínica, actualización 2016. Rev Neurol 2016; 63 (Supl 3): S1-S73–, e incorpora 176 nuevas referencias aparecidas desde entonces, con toda la información disponible para facilitar el acceso a toda la información en un único documento. La revisión se centra en las principales indicaciones del fármaco, como los accidentes cerebrovasculares agudos y sus secuelas, incluyendo el deterioro cognitivo, y los traumatismos craneoencefálicos y sus secuelas. Se recogen los principales aspectos experimentales y clínicos en estas indicaciones


This review is based on the previous one published in 2016 (Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol 2016; 63 (Supl 3): S1-S73), incorporating 176 new references, having all the information available in the same document to facilitate the access to the information in one document. This review is focused on the main indications of the drug, as acute stroke and its sequelae, including the cognitive impairment, and traumatic brain injury and its sequelae. There are retrieved the most important experimental and clinical data in both indications.(AU)


Asunto(s)
Humanos , Citidina Difosfato Colina , Demencia , Neuropsicología , Trastornos del Movimiento , Neurología , Enfermedades del Sistema Nervioso
3.
Rev Neurol ; 63(S03): S1-S73, 2016 Dec 23.
Artículo en Español, Inglés | MEDLINE | ID: mdl-28417449

RESUMEN

This review is based on the previous one published in 2010 -Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol 2011; 52 (Suppl 2): S1-62-, incorporating 183 new references, having all the information available to facilitate the access to the information in one document. This review is focused on the main indications of the drug, as acute stroke and its sequelae, including the cognitive impairment, and traumatic brain injury and its sequelae. There are retrieved the most important experimental and clinical data in both indications.


TITLE: Citicolina: revision farmacologica y clinica, actualizacion 2016.Esta revision se basa en la publicada en 2010 ­Secades JJ. Citicolina: revision farmacologica y clinica, actualizacion 2010. Rev Neurol 2011; 52 (Supl 2): S1-62­ e incorpora 183 nuevas referencias aparecidas desde entonces, con lo que se organiza toda la informacion disponible para facilitar el acceso a dicha informacion en un unico documento. La revision se centra en las principales indicaciones del farmaco, como son los accidentes cerebrovasculares agudos y sus secuelas, incluyendo el deterioro cognitivo, y los traumatismos craneoencefalicos y sus secuelas. Se recogen los principales aspectos experimentales y clinicos en estas indicaciones.


Asunto(s)
Citidina Difosfato Colina/farmacología , Nootrópicos/farmacología , Lesiones Traumáticas del Encéfalo/tratamiento farmacológico , Disfunción Cognitiva/tratamiento farmacológico , Progresión de la Enfermedad , Humanos , Accidente Cerebrovascular/tratamiento farmacológico
4.
Rev Neurol ; 52 Suppl 2: S1-S62, 2011 Mar 14.
Artículo en Inglés, Español | MEDLINE | ID: mdl-21432836

RESUMEN

This review is based on the previous one published in 2006 -Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006; 28 (Suppl B): S1-56-, incorporating the new references until now, having all the information available to facilitate the access to the informacion in one document. This review is focused on the main indications of the drug, as acute stroke and its sequelae, including the cognitive impairment, and traumatic brain injury and its sequelae. There are retrieved the most important experimental and clinical data in both indications.


Asunto(s)
Citidina Difosfato Colina/farmacología , Citidina Difosfato Colina/uso terapéutico , Lesiones Encefálicas/tratamiento farmacológico , Isquemia Encefálica/tratamiento farmacológico , Trastornos Cerebrovasculares/tratamiento farmacológico , Ensayos Clínicos como Asunto , Trastornos del Conocimiento/tratamiento farmacológico , Citidina Difosfato Colina/farmacocinética , Citidina Difosfato Colina/toxicidad , Humanos , Aprendizaje/efectos de los fármacos , Memoria/efectos de los fármacos , Accidente Cerebrovascular/tratamiento farmacológico , Transmisión Sináptica/efectos de los fármacos
5.
Rev. neurol. (Ed. impr.) ; 52(supl.2): s1-s62, 14 mar., 2011. tab, ilus, graf
Artículo en Español | IBECS | ID: ibc-91628

RESUMEN

Esta revisión se basa en la publicada en el año 2006 –Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006; 28 (Suppl B): S1-56– e incorpora las nuevas referencias aparecidas desde entonces, con lo que se organiza toda la información disponible para facilitar el acceso a dicha información en un único documento. La revisión se centra en las principales indicaciones del fármaco, como son los accidentes cerebrovasculares agudos y sus secuelas, incluyendo el deterioro cognitivo, y los traumatismos craneoencefálicos y sus secuelas. Se recogen los principales aspectos experimentales y clínicos en estas indicaciones (AU)


This review is based on the previous one published in 2006 –Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006; 28 (Suppl B): S1-56–, incorporating the new references until now, having all the information available to facilitate the access to the información in one document. This review is focused on the main indications of the drug, as acute stroke and its sequelae, including the cognitive impairment, and traumatic brain injury and its sequelae. There are retrieved the most important experimental and clinical data in both indications (AU)


Asunto(s)
Humanos , Citidina Difosfato Colina/farmacología , Accidente Cerebrovascular/tratamiento farmacológico , Nootrópicos/farmacología , Traumatismos Craneocerebrales/tratamiento farmacológico
6.
Neuropharmacology ; 42(6): 846-54, 2002 May.
Artículo en Inglés | MEDLINE | ID: mdl-12015211

RESUMEN

Citicoline has been demonstrated to be beneficial in several models of cerebral ischaemia. We tested the hypothesis that citicoline may provide apoptotic pathways following focal cerebral ischaemia. Focal cerebral ischaemia was produced by distal, permanent middle cerebral artery occlusion (MCAO) in Sprague-Dawley rats. The animals were randomised into four groups: (B+A) Citicoline 500 mg/kg IP 24 and 1 h before MCAO, and 23 h after MCAO; (A) citicoline 500 mg/kg IP, within 30 min after MCAO, and 23 h after MCAO; (C) vehicle IP; and (D) sham-operated. The animals were sacrificed at 12 h (n=8 per group) and 24 h (n=8 per group) after MCAO. Immunohistochemistry was performed on free-floating tissue sections with goat polyclonal antibodies to procaspase-1, -2, -3, -6 and -8, and in paraffin-embedded sections processed for cleaved caspase-3 (17 kDa) immunohistochemistry. Finally, some sections were stained with the method of in situ end-labelling of nuclear DNA fragmentation. For gel electrophoresis and Western blotting, antibodies to poly (ADP-ribose) polymerase (PARP) products of 89 kDa were used to reveal specific cleavage substrates of caspases. MCAO induced the expression of all procaspases and the expression of PARP products of 89 kDa, as well as cells with nuclear DNA fragmentation, at 12 and 24 h, in the infarcted core and penumbra. Citicoline reduced the expression of all procaspases at 12 and 24 h after MCAO, as well as the expression of cleaved caspase-3 in cells in the penumbra area. This was accompanied by a reduction in the number of cells bearing nuclear DNA fragments. The expression of caspase-cleaved products of PARP (PARP 89 kDa) was reduced in citicoline-treated ischaemic rats. These results show that citicoline inhibits the expression of proteins involved in apoptosis following MCAO.


Asunto(s)
Inhibidores de Caspasas , Citidina Difosfato Colina/farmacología , Fragmentación del ADN/efectos de los fármacos , Precursores Enzimáticos/antagonistas & inhibidores , Infarto de la Arteria Cerebral Media/enzimología , Poli(ADP-Ribosa) Polimerasas/biosíntesis , Animales , Western Blotting , Caspasa 3 , Caspasas/biosíntesis , Núcleo Celular/efectos de los fármacos , Núcleo Celular/genética , Citidina Difosfato Colina/uso terapéutico , Fragmentación del ADN/fisiología , Precursores Enzimáticos/biosíntesis , Femenino , Hidrólisis , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Inyecciones Intraperitoneales , Nootrópicos/farmacología , Nootrópicos/uso terapéutico , Inhibidores de Poli(ADP-Ribosa) Polimerasas , Poli(ADP-Ribosa) Polimerasas/metabolismo , Ratas , Ratas Sprague-Dawley , Especificidad por Sustrato/efectos de los fármacos
7.
Rev Neurol ; 30(1): 27-34, 2000.
Artículo en Español | MEDLINE | ID: mdl-10742992

RESUMEN

INTRODUCTION: Cerebral vasospasm is involved in the development of delayed ischemic lesions in patients with subarachnoid hemorrhage. We developed an integral theoretical model to explain the pathophysiology of cerebral vasospasm, in which endothelin-1 has a pivotal role in the development of both cerebral vasospasm and delayed ischemic neurological deficits (DIND). OBJECTIVE: The objective of this study is to analyze the relationship between temporal profile of plasma endothelin-1 levels and the development of cerebral vasospasm and DIND. PATIENTS AND METHODS: We analyzed sequentially plasma endothelin-1 levels in 17 patients with aneurysmatic subarachnoid hemorrhage. All the patients had complete clinical and neuroradiological studies. Patients were classified according to Fisher's score. RESULTS: Patients (4 males and 13 females, aged 48.1 +/- 20.3 years) had a good clinical condition (Hunt-Hess < 4, GCS > 10). Two weeks after bleeding, patients had higher plasma endothelin-1 levels than healthy volunteers (p = 0.024). Patients who developed DIND had higher plasma endothelin-1 levels (p = 0.034) and a different evolution (p = 0.0146) than patients without DIND. There is a significant correlation (p = 0.02) between basal plasma endothelin-1 levels and GOS score. Multiple regression analysis shows a significant dependence between plasma endothelin-1 levels and Fisher's score (p = 0.0195), development of DIND (p = 0.0095), and GOS score (p = 0.0319). Logistic regression analysis finds a predictive relation between Fisher's score and plasma endothelin-1 levels for the development of DIND (overall predicted = 74.24%; p = 0.0148). CONCLUSIONS: Plasma endothelin-1 levels are increased in patients after subarachnoid hemorrhage and are associated with the development of cerebral vasospasm and DIND.


Asunto(s)
Isquemia Encefálica/etiología , Endotelina-1/sangre , Hemorragia Subaracnoidea/etiología , Vasoespasmo Intracraneal/sangre , Vasoespasmo Intracraneal/complicaciones , Anciano , Especificidad de Anticuerpos/inmunología , Isquemia Encefálica/sangre , Endotelina-1/inmunología , Femenino , Escala de Coma de Glasgow , Humanos , Aneurisma Intracraneal/sangre , Aneurisma Intracraneal/etiología , Masculino , Persona de Mediana Edad , Radioinmunoensayo , Factores de Riesgo , Hemorragia Subaracnoidea/sangre , Tomografía Computarizada por Rayos X , Vasoespasmo Intracraneal/fisiopatología
8.
Rev Neurol ; 30(5): 401-8, 2000.
Artículo en Español | MEDLINE | ID: mdl-10775962

RESUMEN

INTRODUCTION: One of the factors involved in the occurrence of ischemic cerebral lesions following head injury is cerebral vasospasm. We analyze the effect of intravenous nicardipine on the prevention and treatment of posttraumatic cerebral vasospasm. PATIENTS AND METHODS: We made a placebo-controlled, randomised, double-blind pilot study of the effect of nicardipine (intravenously 5 mg/hour for one week) on patients with moderate or severe head injury who presented with cerebral vasospasm, defined as an average Doppler flow velocity (DFV) of 100 cm/second or more. The main variable assessed was the evolution of the DFV and the secondary criteria were the evolution of the arterial blood pressure, coma scales, the findings on the Glasgow Coma Scale and the safety of the drug. RESULTS: Eleven patients were included in each homogeneous group. The DFV was found to have become normal on the first day of treatment with nicardipine and on the third day with the placebo (p = 0.023). During the first day of treatment the percentage of cerebral hemispheres diagnosed as having suspected spasm was 11.1% for nicardipine and 64.3% for the placebo (p = 0.02881). The average time for recovery (DFV < 100 cm/second) was 3.33 days with the placebo and 1.22 days with nicardipine (p = 0.0039). The patients treated with nicardipine had 8.89 times more chance of recovery from vasospasm. The incidence of adverse effects was greater with the placebo (p = 0.014). CONCLUSION: Nicardipine is effective in the reversal and prevention of increased Doppler flow velocity in patients with moderate or severe head injury.


Asunto(s)
Lesiones Encefálicas/tratamiento farmacológico , Nicardipino/uso terapéutico , Vasodilatadores/uso terapéutico , Adulto , Velocidad del Flujo Sanguíneo/fisiología , Presión Sanguínea/fisiología , Encéfalo/irrigación sanguínea , Encéfalo/diagnóstico por imagen , Lesiones Encefálicas/complicaciones , Lesiones Encefálicas/diagnóstico , Método Doble Ciego , Femenino , Escala de Coma de Glasgow , Humanos , Infusiones Intravenosas , Masculino , Proyectos Piloto , Hemorragia Subaracnoidea Traumática/diagnóstico , Hemorragia Subaracnoidea Traumática/etiología , Factores de Tiempo , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Vasoespasmo Intracraneal/diagnóstico , Vasoespasmo Intracraneal/etiología
9.
Methods Find Exp Clin Pharmacol ; 21(9): 633-44, 1999 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-10669911

RESUMEN

Cytidine 5'-diphosphocholine (citicoline) is a an endogenous intermediate in the biosynthesis of structural membrane phospholipids and brain acetylcholine. Citicoline has been extensively used for the treatment of neurodegenerative disorders associated with head trauma, stroke, brain aging, cerebrovascular pathology and Alzheimer's disease. In this study we have investigated the efficacy and safety of the treatment with citicoline versus placebo in patients with Alzheimer disease. Thirty patients (age = 73.0 +/- 8.5 years; range = 57-87 years) with mild to moderate senile dementia (GDS: stages 3-6) of the Alzheimer type were included in a double-blind, randomized and placebo-controlled clinical trial. After a 2-week period of drug washout, patients were treated with i) placebo (n = 17; age = 73 +/- 5 years) or ii) 1,000 mg/day of citicoline (n = 13; age = 76 +/- 9 years) for 12 weeks (84 days). Examinations were done at baseline (T0) and after the 12 weeks of treatment (T12). As compared to placebo, citicoline improved cognitive performance in Alzheimer's disease patients with APOE E4 (ADAS: difference between groups = -3.2 +/- 1.8 scores, p < 0.05; ADAS-cog: difference between groups = -2.3 +/- 1.5, ns); and this improvement on cognition was more pronounced (ADAS, p < 0.01; ADAS-cog: difference between groups = -2.8 +/- 1.3, p < 0.06) in patients with mild dementia (GDS < 5). Citicoline also increased cerebral blood flow velocities in comparison with placebo (p < 0.05) when transcranial Doppler recordings from both hemispheres were considered together, as well as diastolic velocity in the left middle cerebral artery (p < 0.05). Patients treated with citicoline showed an increase in the percentage of brain bioelectrical activity of alpha (occipital electrodes) and theta type (left side electrodes), accompanied by a decrease in relative delta activity particularly marked in the left temporal lobe. Significant differences with respect to placebo (p < 0.05) were observed for theta activity in several fronto-parieto-temporal electrodes of the left hemisphere. Treatment with citicoline tended to reduce serum IL-1 beta levels, mainly after 4 weeks of administration, with no modified blood histamine content. In addition, neither adverse side effects nor alterations in biological and hematological parameters were induced by citicoline. The present data indicate that citicoline (1,000 mg/day) is well tolerated and improves cognitive performance, cerebral blood perfusion and the brain bioelectrical activity pattern in AD patients. According to our results, it seems that citicoline might be a useful treatment in Alzheimer's disease, and that the efficacy of this compound is greater in patients with mild mental deterioration and/or bearing the epsilon 4 allele of the APOE.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Apolipoproteínas E/genética , Encéfalo/irrigación sanguínea , Encéfalo/efectos de los fármacos , Cognición/efectos de los fármacos , Citidina Difosfato Colina/uso terapéutico , Anciano , Enfermedad de Alzheimer/genética , Método Doble Ciego , Electroencefalografía , Femenino , Genotipo , Hemodinámica/efectos de los fármacos , Histamina/sangre , Humanos , Interleucina-1/sangre , Masculino , Persona de Mediana Edad , Nootrópicos/farmacología , Proyectos Piloto , Placebos , Flujo Sanguíneo Regional/efectos de los fármacos , Factores de Tiempo
10.
Neurologia ; 12(8): 339-42, 1997 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9401397

RESUMEN

Seven-three patients diagnosed with vascular dementia (VD) left to their natural evolution have been observed during a period of time of one year. The objective of this study is to find an index to quantify the degree of loss of cognitive capabilities in patients affected by VD, as well as to define the minimum loss of punctuation in this index, that can only be caused by an unfavourable evolution of the disease. This index, which we call Percentual Variation Index (PVI), is based on the evolution of the punctuations of the Cognoscitive Mini-Exam (CME) after a follow-up of one year. Our definition states that in order to consider patients as having cognitive impairment of vascular origin, they must lose more than 10% of their basal CME score in one year. This method could be useful in assessing the therapeutic efficacy of drugs used in treating such illnesses.


Asunto(s)
Trastornos del Conocimiento/diagnóstico , Trastornos del Conocimiento/etiología , Demencia Vascular/complicaciones , Pruebas Neuropsicológicas , Anciano , Femenino , Humanos , Masculino , Modelos Psicológicos
11.
Methods Find Exp Clin Pharmacol ; 17 Suppl B: 1-54, 1995 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-8709678

RESUMEN

Cytidine 5'-diphosphocholine, CDP-choline or citicoline, is an essential intermediate in the biosynthetic pathway of the structural phospholipids of cell membranes, especially in that of phosphatidylcholine. Upon oral or parenteral administration, CDP-choline releases its two principle components, cytidine and choline. When administered orally, it is absorbed almost completely, and its bioavailability is approximately the same as when administered intravenously. Once absorbed, the cytidine and choline disperse widely throughout the organism, cross the blood-brain barrier and reach the central nervous system (CNS), where they are incorporated into the phospholipid fraction of the membrane and microsomes. CDP-choline activates the biosynthesis of structural phospholipids in the neuronal membranes, increases cerebral metabolism and acts on the levels of various neurotransmitters. Thus, it has been experimentally proven that CDP-choline increases noradrenaline and dopamine levels in the CNS. Due to these pharmacological activities, CDP-choline has a neuroprotective effect in situations of hypoxia and ischemia, as well as improved learning and memory performance in animal models of brain aging. Furthermore, it has been demonstrated that CDP-choline restores the activity of mitochondrial ATPase and of membranal Na+/K+ ATPase, inhibits the activation of phospholipase A2 and accelerates the reabsorption of cerebral edema in various experimental models. CDP-choline is a safe drug, as toxicological tests have shown; it has no serious effects on the cholinergic system and it is perfectly tolerated. These pharmacological characteristics, combined with CDP-choline's mechanisms of action, suggest that this drug may be suitable for the treatment of cerebral vascular disease, head trauma of varying severity and cognitive disorders of diverse etiology. In studies carried out on the treatment of patients with head trauma, CDP-choline accelerated the recovery from post-traumatic coma and the recuperation of walking ability, achieved a better final functional result and reduced the hospital stay of these patients, in addition to improving the cognitive and memory disturbances which are observed after a head trauma of lesser severity and which constitute the disorder known as postconcussion syndrome. In the treatment of patients with acute cerebral vascular disease of the ischemic type, CDP-choline accelerated the recovery of consciousness and motor deficit, attaining a better final result and facilitating the rehabilitation of these patients. The other important use for CDP-choline is in the treatment of senile cognitive impairment, which is secondary to degenerative diseases (e.g., Alzheimer's disease) and to chronic cerebral vascular disease. In patients with chronic cerebral ischemia, CDP-choline improves scores on cognitive evaluation scales, while in patients with senile dementia of the Alzheimer's type, it slows the disease's evolution. Beneficial neuroendocrine, neuroimmunomodulatory and neurophysiological effects have been described. CDP-choline has also been shown to be effective as co-therapy for Parkinson's disease. No serious side effects have been found in any of the groups of patients treated with CDP-choline, which demonstrates the safety of the treatment.


Asunto(s)
Citidina Difosfato Colina/farmacología , Citidina Difosfato Colina/uso terapéutico , Nootrópicos/farmacología , Nootrópicos/uso terapéutico , Animales , Disponibilidad Biológica , Trastornos Cerebrovasculares/tratamiento farmacológico , Traumatismos Craneocerebrales/tratamiento farmacológico , Citidina Difosfato Colina/farmacocinética , Demencia/tratamiento farmacológico , Humanos , Nootrópicos/farmacocinética , Enfermedad de Parkinson/tratamiento farmacológico , Distribución Tisular
12.
Cephalalgia ; 13(3): 218, 1993 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8358784
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA